BIIB | Biogen Inc. |
Biological Products (no Diagnostic Substances) |
Book value per $ invested | $ 0.76 |
Leverage | 42.22% |
Market Cap | $ 21.7B |
PE | 13.49 |
Dividend Yield | 0.00% |
Profit | $ 1.6B |
Margin | 17.18% |
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.